Journal of Clinical Lipidology
Volume 4, Issue 3 , Pages 144-151, May 2010

Should we use apoB for risk assessment and as a target for treatment?†

  • W. Virgil Brown, MD

      Affiliations

    • Editor-in-Chief, The Journal of Clinical Lipidology, Charles Howard Candler Professor of Internal Medicine Emeritus, Emory University School of Medicine, 1670 Clairmont Road, Atlanta, GA 30033
    • Corresponding Author InformationCorresponding author.
    • ,
  • Gary L. Myers, PhD

      Affiliations

    • Chief of the Clinical Chemistry Branch at the Centers for Disease Control and Prevention (CDC), Atlanta, GA
    • ,
  • Allan D. Sniderman, MD

      Affiliations

    • Edwards Professor of Cardiology, Professor of Medicine, McGill University Health Centre, Montreal, Quebec, Canada
    • ,
  • Evan Stein, MD, PhD

      Affiliations

    • Director of the Metabolic and Atherosclerosis Research Center, Cincinnati, OH

Received 5 March 2010; accepted 5 March 2010. published online 17 March 2010.

No abstract is available. To read the body of this article, please view the Full Text online.

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 31.50 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Subscribe to this title

    Get unlimited online access to this article and all other articles in this title 24/7 for one year.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.
 

PII: S1933-2874(10)00103-0

doi:10.1016/j.jacl.2010.03.004

Journal of Clinical Lipidology
Volume 4, Issue 3 , Pages 144-151, May 2010

Article Tools

* Image Usage & Resolution